search
Back to results

Bioimpedance and Hand-held Echocardiographay for Clinical Decision-making in Treatment of Cardio-renal Syndrome Type I

Primary Purpose

Cardio-Renal Syndrome

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Providing caring physicians with hemodynamic variables
Sponsored by
HaEmek Medical Center, Israel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardio-Renal Syndrome

Eligibility Criteria

40 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient admitted for acute decompensation of heart failure and developed cardiorenal syndrome (all three criteria below are required):

A. Evidence of heart failure defined by either (i) or (ii) and (iii), where:

(i) is clinical complaints of dyspnea or leg swelling or fatigue (ii) is clinical findings of pulmonary rales, leg edema, or congestion on chest film (iii) is recent (within 1 year of admission) echocardiographic examination demonstrating heart failure B. Patient as in A (above) whos serum creatinine level on admission is 0.3 mg% greater than patient's baseline.

C. Patient capable of submitting informed consent

Exclusion Criteria:

  • Other causes for dyspnea or leg edema (e.g. exacerbation of COPD, pneumonia, liver cirrhosis, hypoalbuminemia, nephrotic syndrome)
  • other causes for acute renal failure (e.g. contrast media nephropathy 10 days prior to admission, use of NSAIDS or antibiotics (aminoglycosides, quinolones), diarrhea, vomiting, rhabdomyolysis, seizures, sepsis.
  • Anemia (Hb<8 gr%)
  • significant bleeding (upper or lower GI, hemoptysis)
  • BMI>40, or BMI<18
  • Signs of a new myocardial infarction by EKG, and increase in troponin levels to levels 1.5 above baseline levels.
  • Hypothyroidism
  • Addison's disease
  • patient on Hemo- or peritoneal dialysis
  • Mechanical ventillation

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Hemodynamic data available

    Hemodynamic data not available

    Arm Description

    Providing caring physicians with hemodynamic variables measured using the NICAS system.

    Hemodynamic variables measured using the NICAS system will not be provided to the caring physicians.

    Outcomes

    Primary Outcome Measures

    Mean hospitalization duration (in days)
    Time of hospitalization is defined from time of recruitment till the time patient is ready for discharge.

    Secondary Outcome Measures

    Time from maximum serum creatinine level to patient's discharge
    Time from maximum serum creatinine level to time when patient is ready for discharge
    Maximum difference in serum creatinine level
    This outcome is defined by the maximum serum creatinine level obtained during the followup of the patient minus patient's mean serum creatinine level

    Full Information

    First Posted
    November 7, 2016
    Last Updated
    June 26, 2019
    Sponsor
    HaEmek Medical Center, Israel
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02959281
    Brief Title
    Bioimpedance and Hand-held Echocardiographay for Clinical Decision-making in Treatment of Cardio-renal Syndrome Type I
    Official Title
    The Application of Bio-impedance System NICAS and Hand-held Echocardiographic System (VSCAN) as Tools for Clinical Decision-making in the Treatment of In-patients With Cardio-renal Syndrome Type I
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2019
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Enrollement failure
    Study Start Date
    June 1, 2018 (Actual)
    Primary Completion Date
    June 16, 2019 (Actual)
    Study Completion Date
    June 16, 2019 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    HaEmek Medical Center, Israel

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to investigate whether hemodynamic data obtained by a noninvasive bio-impedance system (NICAS) sampled from patients with cardiorenal syndrome type I (CRS1) improve clinical outcomes. We hypothesize that hemodynamic data provided to the caring physician will improve management of CRS1 patients.
    Detailed Description
    Patients admitted to the hospital due to acute decompensation of heart failure (ADHF) may manifest some deterioration in their renal function. The latter is associated with unfavorable outcomes: prolonged hospitalization and death. Cardiorenal syndrome type 1 (CRS1) is defined as a deterioration in renal function manifested by an increase in serum creatinine level by >0.3 mg% compared to patient's baseline level. The etiology of CRS1 is not clear and may be related to body fluid overload congesting the kidneys or dehydration reducing perfusion to the kidneys. Body fluid status is affected by diuretics. Presently, the practitioner has no objective data to assess whether CRS1 resulted from fluid overload or dehydration. In this study investigators plan to measure hemodynamic parameters from all patients admitted with CRS1 to our department. Parameters will be measured using the noninvasive bio-impedance system (NICAS). Randomly, patients will be allocated to either a study or control group. In the study group, the hemodynamic variables of the NICAS system will be available to the caring physicians. The physicians will use the data according to their discretion. The hemodynamic system is a decision making supporting system and therefore the physician may use the data according to his/her understanding. In the control group, the hemodynamic variables of the NICAS system will not be available to the caring physicians. We hypothesize that using the NICAS system as a decision making supporting system will improve patient management by decreasing length of hospitalization, and shortening the time interval to reverse creatinine to its baseline level.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cardio-Renal Syndrome

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Hemodynamic data available
    Arm Type
    Experimental
    Arm Description
    Providing caring physicians with hemodynamic variables measured using the NICAS system.
    Arm Title
    Hemodynamic data not available
    Arm Type
    No Intervention
    Arm Description
    Hemodynamic variables measured using the NICAS system will not be provided to the caring physicians.
    Intervention Type
    Other
    Intervention Name(s)
    Providing caring physicians with hemodynamic variables
    Intervention Description
    NICAS electrodes are applied to the skin of the forearm bilaterally (similar to EKG electrodes). Conductors, attached to the electrodes, connect the patient with the measuring system.
    Primary Outcome Measure Information:
    Title
    Mean hospitalization duration (in days)
    Description
    Time of hospitalization is defined from time of recruitment till the time patient is ready for discharge.
    Time Frame
    2 months
    Secondary Outcome Measure Information:
    Title
    Time from maximum serum creatinine level to patient's discharge
    Description
    Time from maximum serum creatinine level to time when patient is ready for discharge
    Time Frame
    2 months
    Title
    Maximum difference in serum creatinine level
    Description
    This outcome is defined by the maximum serum creatinine level obtained during the followup of the patient minus patient's mean serum creatinine level
    Time Frame
    2 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    40 Years
    Maximum Age & Unit of Time
    90 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patient admitted for acute decompensation of heart failure and developed cardiorenal syndrome (all three criteria below are required): A. Evidence of heart failure defined by either (i) or (ii) and (iii), where: (i) is clinical complaints of dyspnea or leg swelling or fatigue (ii) is clinical findings of pulmonary rales, leg edema, or congestion on chest film (iii) is recent (within 1 year of admission) echocardiographic examination demonstrating heart failure B. Patient as in A (above) whos serum creatinine level on admission is 0.3 mg% greater than patient's baseline. C. Patient capable of submitting informed consent Exclusion Criteria: Other causes for dyspnea or leg edema (e.g. exacerbation of COPD, pneumonia, liver cirrhosis, hypoalbuminemia, nephrotic syndrome) other causes for acute renal failure (e.g. contrast media nephropathy 10 days prior to admission, use of NSAIDS or antibiotics (aminoglycosides, quinolones), diarrhea, vomiting, rhabdomyolysis, seizures, sepsis. Anemia (Hb<8 gr%) significant bleeding (upper or lower GI, hemoptysis) BMI>40, or BMI<18 Signs of a new myocardial infarction by EKG, and increase in troponin levels to levels 1.5 above baseline levels. Hypothyroidism Addison's disease patient on Hemo- or peritoneal dialysis Mechanical ventillation
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Guy Dori, MD, DSc
    Organizational Affiliation
    haemek medical center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    IPD Sharing Plan Description
    Investigators do not plan to share the IPD with any body. After completion of study we plan to publish results.
    Citations:
    PubMed Identifier
    22840531
    Citation
    Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol. 2012 Sep 18;60(12):1031-42. doi: 10.1016/j.jacc.2012.01.077. Epub 2012 Jul 25.
    Results Reference
    background

    Learn more about this trial

    Bioimpedance and Hand-held Echocardiographay for Clinical Decision-making in Treatment of Cardio-renal Syndrome Type I

    We'll reach out to this number within 24 hrs